Cipla growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue+2.2%+7.4%
EBITDA−17.5%+5.4%
Net Income−26.7%+10.9%
EPS (adj.)−26.4%+11.5%
Total Assets+13.7%+13.0%
Total Equity+10.3%+13.3%
Free Cash Flow−75.1%−25.2%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

CIPLA₹1,365.60

Cipla Ltd.

· Pharma & Health
₹ CrorePeersSUNPHARMADRREDDYLUPINAPOLLOHOSPMAXHEALTHDIVISLABTORNTPHARMZYDUSLIFEMcap ₹1.10L Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue+2.2+7.4
EBITDA-17.5+5.4
Net Income-26.7+10.9
EPS (adj.)-26.4+11.5
Total Assets+13.7+13.0
Total Equity+10.3+13.3
Free Cash Flow-75.1-25.2
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 146%.